Testosterone Pellets vs Injections: Which Is Easier to Change?

Testosterone pellets vs injections comes down to control versus convenience. Cypionate or enanthate injections are easier for a clinician to adjust; pellets reduce treatment tasks but require an in-person procedure and can last three to six months. Neither is an automatic choice when fertility, high hematocrit, or an unconfirmed diagnosis needs attention. 1 2 3 5

By TRT Provider Guide · Last verified: September 2026

Best fit for easier adjustment: discuss cypionate or enanthate injections. Best fit for fewer treatment events: discuss pellets, provided the longer commitment and procedure fit your clinical situation. Neither is a shortcut around testing or fertility planning. These are practical fit judgments, not a prescription. 1 5

Testosterone pellets vs injections: what changes day to day?

Pellets trade easier day-to-day handling for a longer commitment after implantation. Cypionate and enanthate injections make future treatment changes easier, but a previous injection does not disappear when the next prescription changes. 1 2 3

This is the table we built to answer the question. Every row is sourced further down. The injection column focuses on cypionate and enanthate; long-acting Aveed is a different, clinic-administered option explained below.

Educational information, not medical advice. Testosterone is a prescription medicine, and choosing a treatment format requires an individual evaluation by a clinician.

Scope: U.S. adult men being evaluated or treated for hypogonadism. This is not a guide to treatment in women, adolescents, gender-affirming care, or nonmedical use. Editorial research; not clinician-reviewed.

A quick definition, because it shows up in an important row: hematocrit is the share of your blood made up of red cells. Testosterone can raise it. A high result needs a clinician's assessment; the study's 50% threshold is not a universal instruction to start, stop, or change treatment. 3 5 8

How we make money: TRT Provider Guide may earn commissions from eligible referrals through provider links, including links reached from the program guides on this page. That creates a conflict worth stating plainly. We separate public-source facts from provider claims, identify the limits of the research, and explain when a local or insurance-based care route deserves consideration instead. This page contains no pellet-program booking link. Read our affiliate disclosure.

TRT Provider Guide is the independent decision resource for testosterone replacement therapy — helping U.S. adults understand how low testosterone is evaluated, compare online and local care models and providers, and choose the next step that fits their health needs, fertility plans, budget, state, and care preferences, with every material claim verified and dated.

Who does each one fit?

Pellets may fit someone who values fewer treatment events and accepts an implantation procedure plus slower adjustment. Injections may fit someone who values control over future treatment and accepts a recurring administration routine; clinical suitability still comes first. 1 2 3 5

Pellets are worth discussing if:

• You've been on testosterone long enough to understand your response, and your clinician thinks a longer-acting format is appropriate.
• You've missed injections, or stopped and restarted, more than once — and want to discuss a format that reduces those treatment tasks.
• A partner or young child at home makes a daily gel a real transfer concern. Both pellets and injections avoid that particular issue.
• You can get to a clinic for repeat procedures and the required follow-up.
• You've discussed current and future fertility plans before treatment.
• Your clinician has reviewed your blood count and other risks rather than treating an implant as a way around monitoring. 1 5 7

Pellets may be the wrong practical fit if:

• This is month one and you strongly value easy adjustment while your response is being assessed.
• You've ever been told your hematocrit is high and haven't had that evaluated.
• You want children and haven't discussed how testosterone could affect that plan.
• You want the easiest possible way for a clinician to change future treatment.
• You're paying cash and haven't compared the complete yearly cost.
• Travel to the insertion clinic — or getting help after a complication — would be difficult.

The right TRT provider is not the same for every person. It depends on whether low testosterone has been properly evaluated, your symptoms and health history, your fertility plans, your state, your insurance or cash-pay preference, your treatment-format preference, your budget, and whether online or in-person care is the better starting point. Some situations belong with primary care, urology, endocrinology, reproductive urology, or urgent or emergency care when the symptoms warrant it. Because a general answer can't resolve those for you, use TRT Provider Guide's Find My TRT Path tool to map your situation to the right care route and the questions to ask before you pay.

Are testosterone pellets or injections better?

Neither one is medically superior as a category. They optimize different things: pellets cut how often you handle treatment, and cypionate or enanthate injections give your clinician a shorter feedback loop when something needs to change. Our editorial preference for injections applies to someone prioritizing easier adjustment — not to every man starting therapy. 1 2 3

That verdict is ours, not a guideline's. Here's the reasoning, so you can check it.

Three practical axes help explain the decision:

1. Control. How easily can the clinician change future treatment? With injections, the next administration can be changed. With pellets, the implanted material continues releasing testosterone. 1

2. Commitment. How much treatment is already in your body? Pellets leave a months-long supply under the skin. Cypionate and enanthate are also long-acting preparations, but do not leave a solid implant to remove. 1 2 3

3. Burden. What do you have to do? Injections create a recurring task. Pellets replace that task with repeat clinic procedures — not with an end to blood tests, follow-up, or side-effect monitoring. 1 3 5

When you don't yet know how you will respond, control can matter more. When you've been steady for two years and you keep forgetting Sunday, fewer treatment tasks may matter more. Neither preference overrides a fertility concern, a concerning blood count, or another reason a clinician might recommend a different approach.

So the real question isn't just "which is better." It's "which tradeoff fits my situation?"

What's actually different between a pellet and an injection?

A testosterone pellet is a small solid cylinder placed under the skin, where it releases testosterone over months. An injection delivers a testosterone preparation into muscle or under the skin, depending on the exact product and prescription. Both are prescription Schedule III controlled substances; neither is a legal shortcut around a clinical evaluation. 1 2 3

Testopel: an FDA-approved pellet

Testopel is an FDA-approved testosterone pellet in the United States. Each pellet holds 75 mg of crystalline testosterone and measures about 3.2 mm by 9 mm. The prescribing information checked for this article was revised in July 2025. 1

"FDA-approved" means the product went through federal review for safety, effectiveness and manufacturing quality. That status belongs to the exact product — not to every pellet a hormone clinic offers. 1 6

Cypionate, enanthate, Xyosted: the injectables

Testosterone cypionate includes Depo-Testosterone and FDA-approved generic products. The label describes intramuscular use at 50–400 mg every two to four weeks for replacement in men. That is a description of the label, not a recommended dose for a reader. 2

Xyosted is different and worth knowing about: it's testosterone enanthate in a single-use auto-injector, approved for weekly subcutaneous administration, meaning under the skin. It comes in 50, 75, and 100 mg strengths. A lot of men picturing "injections" are picturing a big intramuscular needle in the glute, and that's not the only version. 3

There is also an important exception to the idea that every injection is easy to change quickly. Aveed, a long-acting testosterone undecanoate injection, has a maintenance interval of ten weeks after its initial schedule. It must be administered in a healthcare setting with observation for at least 30 minutes because of risks including pulmonary oil microembolism and anaphylaxis. It is not the same practical choice as a self-administered weekly product. 4

One thing to be careful about: those label numbers are not a dosing calculator. You can't convert pellet milligrams into weekly injection milligrams on a napkin, and we're not going to help you try. Real prescriptions are individualized, and your clinician sets them against your labs.

Using an approved product outside its labeled instructions is called off-label prescribing. A compounded preparation is different: the finished preparation itself is not FDA-approved. Do not treat those two categories as interchangeable. 6 16

"Pellet" doesn't always mean Testopel

This is a useful thing to check before paying: ask for the exact product name.

Some clinics use compounded pellets made by a compounding pharmacy. Compounded drugs are not FDA-approved. They don't go through federal premarket review for safety, effectiveness or manufacturing quality. 6

Compounding can meet a medical need when an approved drug cannot. But it's a different category, and you should know which one is going in your body. A claim that a compound is "the same" as an approved product requires more than a shared hormone name. 6

In 2023, researchers randomized 75 men with testosterone deficiency to either Testopel (ten 75 mg pellets) or a compounded pellet (eight 100 mg pellets). Testosterone levels were not significantly different between groups at two, four, and six months. PSA, hemoglobin and hematocrit were not significantly different. Estradiol ran higher in the compounded arm at two months — a median of 43 versus 29 pg/mL — but the difference was no longer significant at month four. One extrusion, in the branded arm. 9

That's useful evidence, with one big asterisk: only ten men contributed six-month measurements. Some participants were lost to follow-up; others left that comparison because their testosterone had fallen below the study's reference threshold and they could seek further treatment. It is a small trial with limited long-term follow-up, and one small trial is not the same as FDA review. 9

Ask the question: "Is this Testopel, or a compounded pellet — and which pharmacy makes it?" A direct answer lets you check the right label, research, and cost. An unclear answer leaves a material fact unresolved.

How long do testosterone pellets actually last?

The Testopel label describes adequate effect commonly for three to four months, sometimes as long as six. The studies do not establish one interval that works for every man, and a quoted six-month schedule is not a guarantee that the effect will last that long for you. 1 9 10 11

This is a number that changes the math, so here's the evidence in one place. The rows use different products, study designs, and outcome measures; they are not five measurements of the same thing.

The useful conclusion is a range, not a promise. The threshold used in a study also does not, by itself, diagnose testosterone deficiency or tell your clinician when to repeat an insertion.

Does a higher pellet count reliably buy more months?

Not reliably enough to promise a particular interval. The Pastuszak table's 135-day and 130-day figures do not match its printed equations; they cannot support a five-day comparison here. The larger McCullough series reported longer maintenance with higher counts, and the studies used different groups and methods. 10 11

A higher amount can change the level reached as well as the duration. That is a clinical decision, not a reason to buy extra pellets to stretch a calendar. 10 11

If a clinic offers to "add a couple more so it lasts longer," that's worth a polite question: "What evidence and follow-up will you use to judge whether that is right for me?"

Why this changes your annual cost

A six-month interval implies about two procedures per year. Four months implies about three; three months implies about four. The clinician's plan and actual billing dates determine the number you pay for.

At an unchanged price per procedure, three procedures cost 50% more than two; four cost twice as much as two. That arithmetic concerns the procedure line, not every item in your total care bill.

Use the schedule your clinician expects, then compare a shorter-interval scenario so a third or fourth procedure does not come as a financial surprise.

And here's the follow-up question worth asking

"What happens if symptoms return before the next insertion is due?"

A return of symptoms needs review, not an automatic diagnosis that the pellets have run out. The material may still be releasing testosterone, and symptoms may have another cause. Bring the timing and symptoms to your clinician rather than changing treatment yourself. 1 5

A six-month appointment is not a six-month guarantee.

Which one can you change or stop faster?

Cypionate or enanthate injections are easier to adjust than implanted pellets. The advantage is control over future administrations, not an ability to erase medication already given. Intramuscular cypionate's approximate eight-day half-life means its exposure continues after a clinician changes or stops the prescription. 1 2 3

It's in the PRECAUTIONS section of the Testopel label — the FDA-approved label for the FDA-approved pellet, revised July 2025:

"Pellet implantation is much less flexible for dosage adjustment than is oral administration of or intramuscular injections of oil solutions or aqueous suspensions. Therefore, great care should be used when estimating the amount of testosterone needed. In the face of complications where the effects of testosterone should be discontinued, the pellets would have to be removed." 1

The product's own federally approved labeling compares it to injections and says injections are more flexible. Not a competitor. Not a blog. The label.

Here's what that means in practice. These are reasons for clinical review, not instructions to change a dose yourself.

The differences in this table come from the labels' descriptions of drug release and adjustment, and clinical guidance on blood-count monitoring and fertility. They do not predict how quickly an individual's hormones, symptoms, or sperm production will change. 1 2 3 5 7

What a Medicare contractor says — and what it doesn't

Palmetto GBA's local Medicare billing-and-coding article, in the version effective on September 21, 2026, puts it this way:

"Pellet implantation is much less flexible for dosage adjustment and more invasive than oral medication, nasal administration, transdermal administration or intramuscular injection. This A/B MAC believes that the use of this product should be rare since the 'accepted method of medical practice' is to administer testosterone transdermally, but there may be reasons that require this injectable medication." 18

Two things to be precise about. That's one Medicare contractor's local article, not national Medicare policy — contractors cover different regions and can differ. And it's a coverage document, not a clinical guideline.

The "rare" language is that contractor's coverage position. It is not a conclusion that pellets are inappropriate for every patient, and repeating a label's flexibility warning is not an independent clinical trial. The practical lesson is to check the medical decision and the coverage rules separately.

One honest caveat on the word "reversible"

We're not going to tell you pellets are irreversible. The label describes removal when complications require discontinuing their effects. 1

The accurate distinction is less readily adjustable. Removal involves another procedure, and the clinician must decide whether and how it can be done. Injections still take time to wear off, but future administrations can be changed without removing an implant. 1 2

"Removable" is not the same as "adjustable."

Not sure which side of that tradeoff you're on?

Your hematocrit, your fertility plans and your state all change this answer, and a general comparison can't resolve them for you. Use Find My TRT Path to map your situation to a care route and get the specific questions to ask before you pay anything. The tool is educational and non-diagnostic.

How many pellets will you actually get?

The number depends on the product and your clinician's prescription. Testopel's FDA-approved dosage guideline for men is 150–450 mg — two to six pellets — every three to six months, while several published studies used larger amounts. A study regimen is not a personal dosing recommendation. 1 8 9 10

We put those side by side because "ten pellets" tells you very little without the product and strength.

To be fair about this: FDA explains that clinicians generally may prescribe an approved drug for an unapproved use when they judge it medically appropriate. That does not mean every off-label regimen is appropriate, every insurer will cover it, or a compounded preparation becomes FDA-approved. 16

The difference affects you in two concrete ways.

First, price can depend on the amount. A per-pellet charge increases with pellet count; a bundled procedure quote may work differently. Ask whether the price includes the exact product, number, and strength prescribed, rather than assuming every "insertion" costs the same.

Second, it changes how you read the research. The 2015 study's pellet group received 750–1,050 mg per insertion. Its results describe those patients and those regimens — not necessarily the outcome of a two-to-six-pellet prescription or a different compounded product. 8

Ask the question: "How many milligrams — not just how many pellets?" Pellet counts aren't comparable between clinics when pellet strengths differ. Milligrams still do not make different preparations, injections, or release patterns interchangeable. 1 2 9

Do pellets and injections carry different risks?

Both expose you to testosterone's systemic risks, but each format adds its own. Observational studies found more frequent hematocrit elevations with the injection regimens studied; pellets add an implantation procedure and are less flexible to adjust. Those findings do not establish one universally safer treatment. 1 3 8 12

The number that favors pellets

We're going to give you this straight, because it's an argument on the pellet side and hiding it would make everything else here less believable.

In a 2015 retrospective comparison of 178 men — 47 using gel, 57 injections, and 74 pellets — here's what happened to hematocrit:

Pastuszak et al., Sexual Medicine, 2015; the reported difference was statistically significant, P < 0.0001. 8

The injection group had the higher rate in that comparison. But the groups were not randomly assigned: injection users were younger and had higher baseline hematocrit and testosterone, among other differences. That prevents treating the percentages as the chance that a particular reader will develop a problem. 8

Other data points in the same direction without making the studies interchangeable. Reddy's 2023 matched observational study included 26 men per group and reported a hematocrit rise of 4.4 percentage points with cypionate versus 1.7 percentage points with pellets over 16 weeks. These are changes in hematocrit percentage, not relative increases of 4.4% and 1.7%. 12

Xyosted's FDA label reports that 4.2% of 283 men in its studies reached a hematocrit of 55% or above during treatment lasting up to a year. The average rise at one year was 5.4 percentage points. The threshold, follow-up, and study population differ from the 2015 comparison, so 4.2% cannot be placed beside 66.7% as though they measure the same outcome. 3

If your hematocrit has already been flagged, that should carry real weight with you, and you should say so out loud to whoever you see next.

Three things sit beside those numbers, and all three are true.

One: the pellet group in the 2015 study received 750 to 1,050 mg per insertion — up to more than twice the label maximum. It's a real comparison, but it isn't label-dose pellets versus injections. 1 8

Two: modern comparative safety evidence is limited, but it is not true that pellets have never been compared with injections in a randomized trial. Conway's 1988 crossover trial did that in 15 men using older products and regimens. It does not settle the safety comparison for today's products, and the 2015 and 2023 hematocrit figures above remain observational findings. 8 12 13

Three: easier adjustment does not mean a blood-count problem is fixed in days. A clinician can change future injections more easily than implanted exposure, but the blood count still needs follow-up. Neither format makes a high hematocrit harmless. 1 2 3 5

Injections were associated with more hematocrit elevations in these cohorts. Pellets make the ongoing exposure harder to adjust. Both facts belong in the decision.

If hematocrit is your main worry, neither of these is your obvious first choice without clinical review. Gel had the lowest rate in the 2015 cohort, but that is a reason to discuss alternatives — not proof that gel is safe for every person with a high blood count. Our injections vs gel comparison covers that tradeoff. 8

Risks that come from the pellet procedure itself

The insertion is a small surgical procedure. That means:

• Bruising and bleeding at the site. The label also describes other insertion-site reactions; a worsening problem needs clinical attention.
• Infection. Reported rates vary. One single-site series of 292 Testopel procedures reported one implantation-site infection, about 0.3%.
• Extrusion — a pellet working its way back out through the incision. The label associates implantation with infection and extrusion and says most reported cases in those postmarketing reports occurred within the first month. 1 15

The 0.3% figure is one clinic's retrospective result, not a guaranteed complication rate for your procedure. Product, technique, follow-up, and how complications are counted can differ. 15

With pellets, you're not just choosing a drug. You're choosing a pair of hands. That's why our question list at the bottom asks how many insertions the clinician has personally done — and what happens if you need help afterward. Experience is worth discussing; a confident answer alone is not proof of safety.

A large 2021 report covered 1,204,012 testosterone or estradiol pellet procedures from 2012–2019. The pooled reported complication rate was under 1%, but 85% of the procedures were in women. The male extrusion rate was 2.58%, so the pooled under-1% figure must not be presented as a man's overall Testopel risk. 20

We'll give you the result and its limitations in the same breath: the author was the founder and chief medical officer of the pellet company whose network generated the data; reporting came from that network; and 43% of patients discontinued after the first insertion, with reasons not recorded. This was not a randomized comparison with injections. 20

Risks that come with injections

Injection-site soreness, bruising, and other local reactions can occur. Xyosted's trials reported injection-site reactions in 12.7% of men, and no patient discontinued because of those reactions. That product-specific finding does not cover every injectable formulation or remove testosterone's systemic risks. 3

Aveed has its own serious administration risks and required clinical observation, discussed above. Grouping all injectables under "mostly logistics" would miss a material difference. 4

Risks that belong to testosterone itself, either way

These are reasons monitoring is not optional, although the exact risks and instructions vary by product and patient:

• Blood pressure. In February 2025, FDA required class-wide labeling changes: removal of the boxed-warning language about increased adverse cardiovascular outcomes, based on the TRAVERSE findings, and new or updated blood-pressure warnings. That was not a declaration that all testosterone products are risk-free. Testopel and Xyosted labeling warns about increased blood pressure and says use is not recommended with uncontrolled hypertension. 1 3 21
• Red blood cell count. It needs assessment before treatment and monitoring afterward. 3 5
• Prostate assessment. PSA — prostate-specific antigen — is a blood test used in prostate assessment. Whether and how it is measured before and during treatment depends on age, risk, and the clinician-patient screening discussion; it is not the same fixed schedule for everyone. 5
• Sperm production. Covered in its own section below, because it deserves one. 3 7
• Blood clots. The labels include postmarketing reports of deep vein thrombosis and pulmonary embolism. 1 3

If you get sudden chest pain or trouble breathing, seek emergency care. New pain and swelling in one calf need prompt medical assessment — not a routine message to a telehealth portal. 1 3

What monitoring looks like between treatment events

Before treatment, the clinician should confirm the diagnosis, review fertility goals and health history, and assess relevant baseline risks. Follow-up should review symptoms, adverse effects, blood pressure, testosterone, and blood counts; prostate monitoring is individualized. The timing of a testosterone blood draw matters because a post-injection or post-implant level changes over time. 1 2 3 5

Ask for a written monitoring schedule, including who reviews results and how you reach a clinician between visits. Months between pellet procedures should not mean months with no plan if something changes.

What does each one really cost in a year?

There is no verified nationwide first-year price for either format. Compare the complete care bill: medication or pellets, procedures, consultation, labs, follow-up, supplies, shipping, and any membership. A medication copay, a clinic's insertion quote, and an online program's monthly price are not equivalent totals.

Pellets, line by line

An itemized quote is more useful than a national range assembled from unrelated clinics and different products.

A cost example — not a market price: suppose your own written quote is $1,000 per insertion, including the pellets and procedure. The procedure portion would be:

These are arithmetic examples, not a recommended insertion schedule or a claim about typical clinic prices. Add the actual consultation, labs, follow-up, and other charges that your quote excludes. Use the worksheet below to compare that total with injections.

Injections, line by line

Male Excel's advertised base, calculated: $120 medication + $99 membership = $219 per monthly equivalent. Twelve equivalents plus the listed $99 consultation produce $2,727 before shipping, separately charged testing, prescription changes, and other excluded services. This is a rate-based budget model, not a verified all-in first-year invoice. 23

The medication page describes a 60-day supply billed every other month. Confirm the actual charge dates and supply length before treating a monthly equivalent as your cash-flow schedule. Its displayed injection package also includes thyroid medication and injection supplies; that bundle does not establish that you need thyroid treatment. Ask for the cost of the plan actually prescribed for you. 23

The price-signal test

Here's a useful test, and it takes one question to run:

"What exact product, total milligrams, procedure, and follow-up does this price buy?"

A low quote alone cannot tell you whether the clinic uses Testopel or compounded pellets. Discounts, insurance, product amount, and bundled services can change the number. Comparing a consumer retail drug price with a clinic's procedure bundle does not prove what is being implanted.

You need the product and the itemized quote. Without them, the price may look precise while the comparison is not.

What's not necessarily in the quoted price

Pellet quotes are often a single number, which feels transparent and sometimes isn't. Ask specifically whether it includes:

• The consultation
• Baseline labs and any repeat diagnostic test
• Follow-up lab draws, with their timing
• The follow-up visit
• What happens, and what it costs, if a pellet extrudes
• Any assessment or procedure needed if treatment causes a complication

For an injection program, add the same questions about monitoring, plus supplies, shipping, membership renewals, refill deadlines, cancellation, and access to your records. A lower monthly figure loses its meaning when required costs sit outside it.

If control is what decided it for you, compare the program — not just the syringe

First, the honest part. Male Excel describes fulfillment through compounding pharmacy partners and says some prescriptions may be compounded. That does not identify the finished injectable product every patient receives. Ask for the exact product and pharmacy in writing: a compounded testosterone preparation is not FDA-approved. If having an FDA-approved product is your priority, an independent clinician prescribing an approved product to a pharmacy is a care route worth comparing first. Our TRT treatment options guide walks through the alternatives. 6 24

Compounding is not what makes an injection adjustable. Your clinician still has to authorize the prescription and any changes. Male Excel markets a daily injection protocol, but daily administration is not a benefit exclusive to compounded medication, and it is not a reason to select a provider without checking the testing, monitoring, product, and total cost. 16 23

For a man leaving pellets because the implanted exposure proved a poor fit, easier changes to future treatment may be the point. The next question is whether this particular program delivers the care and product he needs — not whether a compound is somehow easier to prescribe.

See Male Excel's current program requirements, treatment formats and pricing — including what is disclosed about labs, the consultation, ongoing charges, and unresolved questions. This opens our program guide, not a clinical eligibility decision.

Two alternatives, honestly framed. Hone Health lists injection pricing by vial, separate from a complete individualized care quote; its public Plus description does not identify the finished injectable product that every patient would receive. Read our Hone Health review for the questions to resolve. Taurus Meds advertises a $149/month rate, and its company-issued release ties that rate to a six-month plan. Its public sales page also repeats injection-related wording across cards for different treatments. That makes the exact product and current written terms worth confirming before committing — see our Taurus Meds page. 26 27 28

What to confirm before a program charges you again

Get written answers about whether repeat early-morning testing and baseline blood counts are included, which clinician reviews abnormal results, and how to reach that clinician. Ask for the exact medication, whether it is FDA-approved or compounded, and the dispensing pharmacy before accepting an uncertain product description.

Male Excel's pricing page advertises no contract and cancellation at any time, but its terms describe recurring charges and generally final, nonrefundable purchases except where otherwise stated. Cancellation of future billing is not the same thing as a refund for an order already processed. Confirm the cutoff for the next refill and which charges stop when you cancel. 23 25

These checks do not turn this format comparison into a provider ranking. They prevent the correct treatment-format preference from leading to the wrong purchase.

Does insurance cover pellets or injections?

Either can be covered, depending on the product, diagnosis, benefit, and plan rules. The pellet product and its insertion have different billing codes, while an injectable may be covered through a pharmacy or medical benefit. Do not assume one format is nationally cheaper or more widely covered from two insurer policies. 18 19 22

A few things worth knowing:

The billing code for 75 mg testosterone pellets changed on January 1, 2026. Cigna's published coding table lists J1073 effective January 1, 2026, and S0189 only through December 31, 2025. UnitedHealthcare's commercial policy effective January 1, 2026 also lists J1073. A coding problem can affect a claim, but an old code is not the only possible reason for a denial. 19 22

Pellets and insertion are separately identifiable services. J1073 describes testosterone pellet, 75 mg; CPT 11980 identifies subcutaneous hormone-pellet implantation. Separate codes do not guarantee separate payment or coverage: billing edits, benefit design, and medical-necessity requirements still matter. 18 19

Off-label prescribing and insurance payment are separate questions. The current Palmetto GBA local article says insertion of more than six pellets every three months is not reasonable and necessary under that policy. That is a real coverage issue for a patient whose proposed amount exceeds it, not a national rule that every larger prescription is unlawful. 18

Cigna and UnitedHealthcare publish their own clinical coverage criteria. Confirm the applicable plan's diagnostic documentation, prior-authorization requirements, product restrictions, and patient responsibility instead of assuming a clinic's acceptance of insurance guarantees payment. 19 22

What to ask your insurer, before you book anything

1. Is this exact product covered — Testopel, or the specific injectable being prescribed?
2. Is the insertion procedure covered separately?
3. Does either one need prior authorization?
4. Do I have to use a specific pharmacy or a specific clinician?
5. Are the baseline and follow-up labs covered?
6. What's my deductible and coinsurance on each piece?

If you have coverage, start with that comparison

Let's be direct about this: a cash-pay online program is not automatically the best place to spend your money.

If your plan covers an appropriate FDA-approved product, compare an in-network clinician and pharmacy quote before paying for a cash-pay membership. That may offer better value for you, but the answer depends on your deductible, copays, required visits, labs, and the actual program quote — not a claim that no online provider can ever cost less. 19 22

Cash-pay telehealth may still matter when access, scheduling, or care coordination is the problem. Decide which problem you need solved before paying for a different care model.

Can you get testosterone pellets online?

Not as an entirely remote procedure. A clinician must physically implant the pellets, although consultation, prescribing, or coordination may involve telehealth when appropriate and lawful. Injections may be managed remotely under applicable federal and state requirements, but some injectable products still require in-person administration. 1 4 17

What the federal rule says, and when it runs out

The DEA and HHS issued a fourth temporary extension of the COVID-era telemedicine flexibilities, effective January 1, 2026 through December 31, 2026. Under its conditions, a DEA-registered practitioner may prescribe Schedule II–V controlled medications through audio-video telemedicine without a prior in-person medical evaluation. The prescription still must meet applicable federal and state requirements. 17

For testosterone, do not read the extension as permission to prescribe from a questionnaire alone. The audio-only provisions for certain opioid-use-disorder medicines are not a general audio-only exception for testosterone. 17

Two conditions actually affect you: the clinician needs the required authority where you are located, and state law or the clinical situation may require an in-person visit. Male Excel itself states: "Based on DEA and state laws, your testosterone treatment plan may require an in-person medical exam." That is a provider statement, not a state-by-state clearance. 17 23 25

We're not going to turn a regulatory deadline into a countdown clock. It's just a fair question to ask any online program: what happens to my refills if the rules change?

When the right answer is a pellet clinic

The online injection guides linked here do not arrange an implantation. A provider's preference for the formats it sells is not independent proof that those formats are better.

If pellets are the format you and your clinician choose, this page has no pellet-program booking link. Find a clinician who performs insertions and can explain the follow-up and complication plan. Take the twelve questions below with you.

What if you want kids in the next few years?

Both formats can suppress sperm production, so choosing pellets instead of injections does not remove the fertility concern. Testosterone from outside the body can suppress the brain signals that support testicular testosterone and sperm production. The degree of suppression and the chance or timing of recovery vary. 3 7

Spermatogenesis is the medical word for making sperm.

The guidance here is not subtle. The AUA/ASRM male infertility guideline says testosterone monotherapy should not be prescribed to a man interested in current or future fertility; it labels that statement a clinical principle. The Endocrine Society recommends against starting testosterone in men planning fertility in the near term. Neither statement makes a favorable blood testosterone result a fertility clearance. 5 7

Xyosted's FDA label puts it plainly:

"Reduced fertility is observed in some men taking testosterone replacement therapy. The impact on fertility may be irreversible." 3

We're not going to soften that, and we're not going to overstate it either. It does not say every man becomes infertile. It warns that reduced fertility can occur and that recovery cannot be promised.

If kids are on the table

This is a reason to make an appointment before choosing a format.

See a urologist, reproductive urologist, or endocrinologist who can address fertility before treatment. A purchase form is not that evaluation. The clinician can review hormones, reproductive history, and whether an examination or semen analysis is needed. 5 7

You may also hear about clomiphene, enclomiphene, hCG, or aromatase inhibitors. But none of them is testosterone, none of them is a "delivery format" of TRT, and nobody should be calling them "natural TRT." The AUA/ASRM guideline discusses selected use of hCG, aromatase inhibitors, or selective estrogen receptor modulators for infertile men with low testosterone; it does not guarantee preserved fertility. It also explains that clomiphene use in men is not FDA-approved. 7

These are separate drug and indication questions, not interchangeable alternatives to a pellet or injection. Their risks, approval status, and suitability need product-specific review with a fertility-aware clinician — not a promise from a format comparison page.

Can you switch from pellets to injections?

Yes, a clinician can plan a switch between treatment formats. The practical constraint is the testosterone still being released from the pellets, so the handover must use your treatment history, current findings, and follow-up — not a fixed waiting period from this page. 1 2 5

What to bring to the new prescriber

"I was on pellets" is not enough to reconstruct the treatment. Bring:

• Your insertion dates. All of them, not just the last one.
• Your dose in milligrams, pellet count, and strength. The product record matters as much as the number of pellets.
• Whether they were Testopel or compounded, and which pharmacy made them.
• Your most recent labs, including testosterone, hematocrit, and any prostate testing your clinician has ordered.
• When your last labs were drawn relative to your last insertion. A level drawn three weeks after insertion and a level drawn at month four tell different stories. 1 5 10

You're entitled to ask for your records. Under HIPAA, patients generally have a right to copies of records held by covered providers, with limited exceptions and permissible copying charges. A provider cannot deny a copy simply because the treatment bill is unpaid. Ask how to submit the request, how it will be delivered, and whether a lawful fee applies. 29

What to expect

Ask your new clinician when to start, based on where you are in the pellet cycle and what your labs show. Don't guess, and don't stack a new therapy on top of an old one because you feel flat.

The clinician also needs to know about side effects, fertility plans, and why you want to switch. Changing providers does not remove the effects of the previous prescription. 1 2 5

Going the other direction

Switching to pellets may be worth discussing when fewer treatment tasks matter more than rapid adjustment. Knowing your previous response helps the discussion, but a stable injection dose is not a direct pellet-conversion formula. 1

If you're new to testosterone therapy and a clinic is recommending pellets as your first format, it's fair to ask why that format fits your needs and how it will handle a poor response. That is a question to answer, not proof the clinic is doing something wrong.

If you're discussing a switch with your clinician

The handover is the whole job. Whoever takes over needs your insertion dates, your dose in milligrams, and your recent hematocrit.

Review what Male Excel requires before prescribing — the disclosed intake process, the formats it offers, pricing, and questions to confirm. This is an editorial program guide; a clinician decides whether treatment is appropriate.

Not sure an online program is even the right care route after a pellet clinic? Use Find My TRT Path to compare the questions to ask about online and local care.

Before either one: has low testosterone actually been confirmed?

A diagnosis needs compatible symptoms or signs plus consistently low, accurately measured testosterone — not one number or a symptom quiz. Testopel and Xyosted labeling require low morning testosterone on at least two separate days before treatment. The Endocrine Society specifies repeat morning, fasting testing and appropriate laboratory methods and reference ranges. 1 3 5 30

Total testosterone is the total amount of the hormone in your blood, bound and unbound. It's the usual first test. Hypogonadism means inadequate hormone production arising from a problem in the testicles or in the brain signals that control them; further testing helps identify the cause. 5

The key checks are:

• Symptoms or signs that fit the diagnosis, together with repeated low results. A number alone isn't testosterone deficiency.
• Appropriate repeat early-morning testing. The Endocrine Society's July 2026 statement again calls for at least two early-morning, fasting measurements.
• A reliable assay and the right reference range. A threshold near 300 ng/dL is commonly used, but it is not a universal diagnosis or an automatic reason to prescribe. Free testosterone may matter when clinically indicated.
• An evaluation of the cause and relevant risks. LH and FSH — hormones involved in signaling the testicles — can help distinguish testicular from pituitary or hypothalamic causes. Blood counts, fertility goals, and appropriate prostate assessment also matter. 3 5 30

Why repeat testing? Testosterone varies, and illness, other health factors, and differences between laboratory methods can affect the result. The clinician needs a consistent picture rather than a single number taken out of context. 5 30

If you're comparing delivery formats before anyone has confirmed you need treatment, you're ahead of the medical decision. A clinic's sales presentation cannot supply the missing diagnosis.

Some situations belong with a clinician or specialist before choosing a format: very abnormal labs, testicular or pituitary concerns, infertility, a history of prostate or breast cancer, a hematocrit that's already high, untreated severe sleep apnea, or a recent heart attack or stroke. These need primary care, urology, endocrinology, or another appropriate clinical assessment — not a purchase decision based on this table. 5

So who should choose which?

Think in constraints, not winners. The table below matches practical preferences to a discussion — not a medical clearance — and the fertility, diagnosis, and safety rows take priority over convenience. 1 5 7

What twelve questions should you ask before a pellet insertion?

Before an insertion, get clear answers about the product, total amount, clinician, price, follow-up, and plan for complications. A complete answer helps you compare clinics; it does not guarantee that treatment is appropriate or that no complication will occur.

This is the page's takeaway. Print it, screenshot it, or write it on the back of an envelope — but take it with you.

We built it because the pellet decision depends on the specific product, clinic, clinician, and care plan — not just a brand name or a promise of fewer visits.

The product and monitoring questions come from the labels and clinical guidance; the records question reflects HHS access guidance. The checklist is our editorial way of turning those requirements and practical uncertainties into a usable conversation. 1 3 5 29

The two that identify what you're actually getting are #1 and #3. If a clinic can't tell you the product and the milligrams, the research becomes difficult to apply to your situation.

Run your own numbers

Fill this in with the actual quote you were given, not an assumed national average. Treat each blank as a place for your quote — not as zero.

Pellet total: initial evaluation and testing + (price per insertion × actual number of insertions) + other required annual charges − applicable insurance payment.

Injection total: initial evaluation and testing + (price per medication fill × number of fills) + membership + other required annual charges − applicable insurance payment.

Do not double-count a bundled service. If you enter your copays or other patient-responsibility amounts, do not subtract the insurer's payment again. If a required charge is still unknown, label the result a known-cost subtotal rather than a complete total.

Two rules when you fill it in: use the clinician's expected insertion schedule, and test the cost of a shorter interval rather than assuming everyone needs exactly two or three procedures. Leave anything you couldn't get a straight answer on blank instead of guessing — a blank row is information.

For an ongoing-year comparison, remove genuinely one-time startup charges but retain repeat visits, labs, procedures, supplies, and any annual fees. Use actual refill and billing dates when comparing cash due during a calendar year.

What did we actually verify?

We checked the public labels, clinical guidance, research papers, coverage documents, and provider statements used in this comparison. We did not test treatment, open a patient account, or independently audit a provider's clinical care.

Verification date: September 21, 2026

Read directly: current posted prescribing information for Testopel, Depo-Testosterone, Xyosted, and Aveed; FDA compounding, off-label-use, and testosterone labeling materials; Endocrine Society guideline resources and its July 2026 statement; AUA/ASRM male infertility guidance; the DEA/HHS fourth temporary extension; the version of Palmetto GBA's Medicare article effective on the verification date; Cigna and UnitedHealthcare's published coverage documents; the research cited here; and the official provider pages linked in our sources.

Confirmed in those sources: product identity and labeled administration; Testopel's adjustment warning; cypionate's approximate eight-day half-life; the repeat morning-testing requirements; the study figures and their stated populations; the change from S0189 to J1073; and the current extension's December 31, 2026 end date. Published research results are identified as what the studies reported, not as predictions for an individual. We also checked the Pastuszak 2012 duration table against its printed equations and identified the mismatch described above.

Provider-stated, not independently verified: Male Excel's prices, bundled services, pharmacy-partner description, access, and billing terms; Hone's starting per-vial price; and Taurus Meds' advertised price, plan description, and product-card content. A public page confirms what a provider states, not whether every patient receives that service or has the same outcome.

Could not establish from public information alone: a complete individualized first-year invoice for these providers, each reader's repeat-test charges, the finished injectable product and pharmacy every patient would receive, state-specific clinical availability for an individual, or what a particular pellet clinic would charge. We do not publish a national pellet-price average or an insured injection total as though those gaps were resolved.

Not established for any individual: your dose, your ideal schedule, your response, your total insurance cost, or which format your clinician should recommend. Those require an evaluation.

How did we compare these two?

We compared the two treatment formats using product-specific evidence rather than treating every pellet or injection as identical. We used How We Review TRT Providers, our documented editorial method, to separate source types and evaluate the commercial claims.

For this page, that meant working in a fixed order. Current FDA labeling and federal regulatory sources first. Clinical guidance for diagnosis, monitoring, and fertility. Peer-reviewed literature for the format tradeoffs. Provider prices with their dates and exclusions attached, never averaged into a single fake number. Clinic marketing claims were read, but never treated as medical evidence.

We keep four things visibly separate throughout: verified fact (a label, a guideline, a federal document), provider-stated fact (what a company says about itself), customer-experience signal (what people report, which can describe a pattern but can't establish safety or effectiveness), and editorial conclusion (our judgment, grounded in the verified facts and labeled as ours).

This page does not use testimonials or claim firsthand treatment experience. The decision tables, twelve-question checklist, and cost worksheet are original editorial tools assembled from the cited sources, not a numerical medical score.

Our preference for easier-adjusted injections when control is the reader's priority is an editorial conclusion. The label quotes and study numbers are checkable source claims. Neither a citation nor a provider's inclusion amounts to a personal medical recommendation.

TRT Provider Guide is the independent decision resource for testosterone replacement therapy care. Read our Editorial Standards and Source Policy, affiliate disclosure, and corrections policy for accountability and how to report an error.

Frequently asked questions

The main tradeoff is fewer treatment events with pellets versus easier changes to future cypionate or enanthate injections. The answers below keep product differences, evidence limits, and the need for individual evaluation in view. 1 2 3 5

Are testosterone pellets better than injections?

Neither is better as a category. Pellets reduce how often you handle treatment; cypionate and enanthate injections make future treatment easier to change. That does not establish injections as the best first treatment for every man. 1 2 3

How long do testosterone pellets last?

The Testopel label describes adequate effect as commonly three to four months, sometimes as long as six. Research results vary. The 2023 trial's reported 82% falling below 300 ng/dL must be read alongside withdrawals and the fact that only ten men contributed six-month measurements. 1 9 11

How often are testosterone injections given?

It depends on the product and the prescription. The Depo-Testosterone label describes intervals of two to four weeks, Xyosted is weekly, and Aveed has a ten-week maintenance interval after its initial schedule. These are product descriptions, not instructions to set or change your treatment. 2 3 4

Can testosterone pellets be adjusted after they're inserted?

Not the way a future injection can be changed. The material keeps releasing until it dissolves. The FDA label specifically says pellet implantation is much less flexible for dosage adjustment than injections. 1

Can testosterone pellets be removed?

The label says they would have to be removed when a complication requires discontinuing testosterone's effects. That requires a clinical assessment and another procedure. "Removable" is not the same as "adjustable," and it is not a promise of instant reversal. 1

Are testosterone pellets FDA approved?

Testopel is. Compounded testosterone pellets are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness, or quality. Ask which exact product you're being offered. 1 6

Do pellets cause fewer hormone swings than injections?

Pellets provide prolonged release, but nobody should promise perfectly flat levels. The pattern depends on the pellet product and amount; injection fluctuations depend on the product and schedule. An older randomized crossover trial found more week-to-week variation with the specific injection regimen it studied, not with every modern injection plan. 1 10 13

Do pellets raise hematocrit less than injections?

The 2015 retrospective cohort found elevations more often with its injection regimens: 66.7% versus 35.1% using the study's 50% threshold. That was not a randomized safety comparison, and a different threshold or population gives a different number. Both formats require monitoring. 8

Which one costs more?

Your itemized quote decides that — not one national average. Pellet costs depend on the product, procedure price, and number of insertions; injection costs depend on medication, visits, labs, supplies, and any program fees. Male Excel's published starting components produce a $2,727 twelve-month base model before excluded charges, not an all-in total. 23

Does insurance cover testosterone pellets?

Some plans cover them under defined criteria. Ask about both the drug and insertion, prior authorization, amount limits, and your patient responsibility. Cigna's coding table lists J1073 from January 1, 2026, replacing its use of S0189 through December 31, 2025; the applicable coverage policy still matters. 18 19 22

Can I get pellets through an online TRT program?

Consultation or coordination may involve telehealth, but the implantation must happen in person. That is different from saying pellets can never be prescribed or discussed remotely. Whether a particular service is available depends on the clinician, program, and applicable requirements. 1 17

Do pellets or injections affect fertility differently?

Neither format avoids the sperm-suppression risk of exogenous testosterone. Xyosted's label warns that reduced fertility occurs in some men and may be irreversible. Discuss present or future fertility goals with a fertility-aware clinician before choosing either format. 3 7

Do I need low testosterone confirmed before choosing either one?

Yes. The labels require low morning testosterone on at least two separate days, and clinical guidance also requires compatible symptoms or signs and properly interpreted testing. Neither one low result nor a questionnaire supplies the diagnosis. 1 3 5

Sources

These links identify the evidence used for medical, regulatory, coverage, and provider-specific statements. Provider sources establish their published claims and prices; they are not used to prove treatment safety or effectiveness.

Product labels, FDA, and federal requirements

• 1. Testopel prescribing information, DailyMed. Product identity, labeled use, duration, warnings, and adjustment; labeling revised July 2025.
• 2. Depo-Testosterone prescribing information, DailyMed. Testosterone cypionate, intramuscular administration, pharmacokinetics, and warnings.
• 3. Xyosted prescribing information, DailyMed. Weekly subcutaneous enanthate, blood-count and injection-site study findings, blood pressure, and fertility warning.
• 4. Aveed prescribing information. Long-acting undecanoate, clinical administration, observation, and boxed warnings.
• 6. FDA: Compounding and the FDA — Questions and Answers. Approval and quality-review distinctions.
• 16. FDA: Understanding Unapproved Use of Approved Drugs — Off Label. What off-label prescribing does and does not mean.
• 17. DEA/HHS: Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications. Federal Register, December 31, 2025; effective January 1–December 31, 2026.
• 21. FDA: Class-wide labeling changes for testosterone products. February 28, 2025 action on cardiovascular boxed-warning language and blood-pressure warnings.
• 29. HHS: Your Medical Records. Access rights, limits, and permissible charges.

Clinical guidance

• 5. Endocrine Society: Testosterone Therapy for Hypogonadism Guideline Resources. Diagnosis, evaluation of cause, contraindications, fertility, and monitoring.
• 7. AUA/ASRM: Diagnosis and Treatment of Infertility in Men, Part II. Exogenous testosterone, fertility goals, and selected non-testosterone therapies.
• 30. Endocrine Society: Statement on Testosterone Replacement Therapy, July 16, 2026. Diagnostic quality, repeat morning testing, and evidence limitations.

Peer-reviewed studies

• 8. Pastuszak et al. Comparison of the effects of testosterone gels, injections, and pellets. Sexual Medicine, 2015;3:165–173. Retrospective hormone and hematocrit comparison.
• 9. Kresch et al. Efficacy and safety outcomes of a compounded testosterone pellet versus a branded testosterone pellet. Sexual Medicine, 2023;11:qfad007. Single-center randomized trial; follow-up limitations explained in the article.
• 10. Pastuszak et al. Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets. Journal of Andrology, 2012. Retrospective study and model estimates.
• 11. McCullough et al. A multi-institutional observational study of testosterone levels after Testopel insertion. Journal of Sexual Medicine, 2012;9:594–601. Six-center series, 380 men and 702 insertions.
• 12. Reddy et al. Prevalence of secondary erythrocytosis in men receiving testosterone therapy: a matched cohort analysis. Canadian Urological Association Journal, 2023. Intranasal testosterone, cypionate, and pellet groups.
• 13. Conway et al. Randomized clinical trial of testosterone replacement therapy in hypogonadal men. International Journal of Andrology, 1988;11:247–264. Historical crossover comparison; not a modern Testopel safety trial.
• 14. Kaminetsky et al. A phase IV prospective evaluation of extended-release testosterone pellets. Journal of Sexual Medicine, 2011;8:1186–1196. Open-label pellet study.
• 15. Cavender and Fairall. Subcutaneous testosterone pellet implant therapy: a single-site retrospective safety analysis. Journal of Sexual Medicine, 2009;6:3177–3192. Eighty men and 292 procedures.
• 20. Donovitz. Low complication rates of testosterone and estradiol implants in over 1 million procedures. Therapeutic Advances in Endocrinology and Metabolism, 2021. Mixed-sex network data; company affiliation and follow-up limitations disclosed above.

Coverage documents

• 18. Palmetto GBA: Billing and Coding — Treatment of Males with Low Testosterone, A58828, version 15. The version effective April 2–September 30, 2026; a local Medicare article, not national coverage policy.
• 19. Cigna: Testosterone Injectable and Implant coverage policy. Clinical and coding criteria; J1073/S0189 transition table.
• 22. UnitedHealthcare: Testosterone Replacement or Supplementation Therapy commercial policy. Effective January 1, 2026; coverage and coding criteria.

Commercial sources: provider-stated, checked September 21, 2026

• 23. Male Excel: HRT costs. Consultation, injection-package pricing, required membership, billing basis, and exclusions.
• 24. Male Excel: Published intake, monitoring, and fulfillment description. Used only for what the provider says about its process and compounding partners — not as medical evidence.
• 25. Male Excel: Terms and Conditions. Recurring billing, purchases, and refund provisions.
• 26. Hone: Men's Plus membership and hormone-optimization information. Starting injection price per vial and plan descriptions.
• 27. Taurus Meds: Published testosterone offer. Current advertised intake and monthly rates; product-card disclosures.
• 28. Taurus Medical company-issued release, May 28, 2026. Dated six-month and month-to-month plan descriptions; not an independent review or a substitute for current written purchase terms.

Where should you go from here?

If you've resolved the format tradeoff, the next step is to discuss the exact product, monitoring plan, and complete quote with a clinician. If diagnosis, fertility, or care access is still unresolved, settle that before choosing a program.

If you're comparing formats more broadly, our TRT treatment options guide covers gels, creams and oral products alongside these two. If hematocrit is your main concern, injections vs gel explains that comparison without turning study percentages into personal medical advice.

Still not sure which TRT care route fits you? Use our free Find My TRT Path tool. It's educational and non-diagnostic: it won't confirm low testosterone, determine eligibility, or guarantee a prescription. It helps organize your care-route questions before you pay. Read the privacy policy before providing information through site tools.

This page is educational information, not medical advice. Testosterone is a Schedule III controlled substance and requires a valid prescription. Do not start, stop, or change treatment based on this comparison. Sudden chest pain or trouble breathing calls for emergency care; new pain and swelling in one leg needs prompt medical assessment.